knowledge -WSS

knowledge

author：knowledge 2025-09-14 21:54:53 - browse：6

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Parkland mass shooting to be reenacted for lawsuit

explore

WSS

Pediatricians' group reaffirms support for gender

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

Texas board proposes rules on abortion law emergency exemption

Readout Newsletter: Illumina, CRISPR, Regeneron

Cancer, immunology, HIV research ensnared in fetal tissue politics

focus

knowledge

focus

As demand for Covid shots wanes, Moderna seeks its next success

With Wegovy coverage, Medicare patients may face high costs

Medical records are filled with copy

Pfizer, Moderna say biotech, pharma drug development is a sprint

Drug repurposing or repositioning? The language matters

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Novavax promises a turnaround & Lilly roils the obesity market

Climate activists disrupt London Pride march to protest corporate sponsorship

Novavax promises a turnaround & Lilly roils the obesity market

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

hotspot

Pharma needs to include young adults in clinical research

U.K. officials, researchers try to ease path for bespoke genetic treatments

'Patient friction coefficient' can gauge a clinical trial's patient burden

Special counsel alerts court to Trump’s social media post

Pediatricians' group reaffirms support for gender

Special counsel alerts court to Trump’s social media post

leisure time

explore

explore

entertainment